ROCKVILLE, Md., May 15, 2015 /PRNewswire/ — TissueGene, Inc. announced today that it has reached an agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design, endpoints and statistical analysis plan for a Phase